Abstract:The development of activatable photosensitizers to allow for the reversible control of singlet oxygen (1O2) production for photodynamic therapy (PDT) faces great challenges. Fortunately, the flourishing field of supramolecular biotechnology provides more effective strategies for activatable PDT systems. Here, we developed a new reversible PDT on a switch that controls the 1O2 generation of self-assembled albumin nanotheranostics in vitro and in vivo. A new molecular design principle of aggregation-induced self-quenching photochromism and albumin on-photoswitching was demonstrated using a new asymmetric, synthetic diarylethene moiety DIA. The photosensitizer porphyrin and DIA were incorporated as building blocks in a glutaraldehyde-induced covalent albumin cross-linking nanoplatform, HSA–DIA–porphyrin nanoparticles (NPs). More importantly, the excellent photoswitching property of DIA enables the resultant nanoplatform to act as a facile, switchable strategy for photodynamic-immunotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/jacs.0c12851?goto=supporting-info">https://pubs.acs.org/doi/10.1021/jacs.0c12851</a>.Discussions of materials and methods used, synthetic protocols, synthesis and optimization of HSA–DIA–porphyrin nanoparticles, 1O2 measurement, cell cultures, CLSM evaluation, in vivo PDT treatment and pathology analysis, abscopal effect on 4T1 tumor-bearing mice, and mechanism investigation of the in vivo combined therapy, figures of synthetic pathway, 1H NMR and HRMS spectra, DIA pictures, NanoDIA in different concentrations, absorption spectra, absorption changes, parallel and antiparallel conformations structures, energy-minimized structures, binding modes, free energy of binding, fluorescence spectra, flow cytometric profiles and corresponding quantitative results, cell viability, histological analysis, morbidity-free survival rate, and histograms depicting variations in the routine blood test and kidney functional markers test, table of binding energies (<a class="ext-link" href="/doi/suppl/10.1021/jacs.0c12851/suppl_file/ja0c12851_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Photoswitchable PROTACs for Reversible and Spatiotemporal Regulation of NAMPT and NAD+

Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation

A Photoactivatable Upconverting Nanodevice Boosts Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers

Light-induced Control of Protein Destruction by Opto-Protac.

PHOTACs enable optical control of protein degradation

Photoswitchable Ultrafast Transactivator of Transcription (TAT) Targeting Effect for Nanocarrier‐Based On‐Demand Drug Delivery

Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase

Development of Visible-Light-activatable Photocaged PROTACs

A PROTAC Augmenter for Photo‐driven Pyroptosis in Breast Cancer

Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives

Activatable Type I Photosensitizer with Quenched Photosensitization Pre and Post Photodynamic Therapy.

Protein-Activatable Diarylethene Monomer as a Smart Trigger of Noninvasive Control Over Reversible Generation of Singlet Oxygen: A Facile, Switchable, Theranostic Strategy for Photodynamic-Immunotherapy

Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy

Repurposing AS1411 for constructing ANM-PROTACs

A Self-Immobilizing Photosensitizer with Long-Term Retention for Hypoxia Imaging and Enhanced Photodynamic Therapy

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

A Photoactivatable Upconverting Nanodevice Boosts the Lysosomal Escape of PROTAC Degraders for Enhanced Combination Therapy

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery